Phase 3 N=135 The Effect Of Oral Ibandronate In Male Osteoporosis
Male Osteoporosis
Primary: Mean Percent Change in BMD of the Lumbar Spine From Baseline to Month 12 — .94; 3.52 percent — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=9,406 EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED)
Myocardial Ischemia · Acute Coronary Syndrome
Primary: Incidence of the Composite of Death, Myocardial Infarction (MI), Recurrent Ischemia Requiring Urgent Revascularization (RI-UR), and Thrombotic Bail-out. — 9.3; 10.0…
Phase 3 N=152 Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)
Infections, Papillomavirus · Papillomavirus Vaccines
Primary: Number of Subjects Seroprotected Against Hepatitis B Following 3 Doses of Engerix — 70; 73 Participants
Phase 3 N=258 An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Advance-Stage Parkinson's Disease
Parkinson's Disease
Primary: Number of Subjects With at Least One Adverse Event During This Open-label Extension Study — 258 Subjects
Phase 3 N=225 A Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine/Cervarix TM Vaccine in Healthy Females Aged 15-25 Years
Infections, Papillomavirus
Primary: Number of Subjects Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies — 125; 2; 122; 3 Participants
Phase 3 N=857 Study to Compare the Efficacy and Safety of Pitavastatin and Simvastatin
Hypercholesterolemia · Dyslipidemia
Primary: Percent Change From Baseline in Low Density Lipoprotein-cholesterol (LDL-C) at 12 Weeks — -38.99; -34.97; -43.97; -42.84 Percent change
Phase 3 N=830 Study to Compare the Efficacy of Pitavastatin With That of Atorvastatin in Lowering Cholesterol Levels
Primary Hypercholesterolemia · Dyslipidemia
Primary: Percent Change From Baseline Low Density Lipoprotein-cholesterol (LDL-C) at Week 12 — -37.89; -38.76; -45.5; -43.9 percent change
Phase 3 N=1,097 Telmisartan/Amlodipine (80/5) vs. Telmisartan/Amlodipine (40/5) vs. Amlodipine 10 or 5 in Resistant Hypertension
Hypertension
Primary: Change From Baseline in Trough Seated Diastolic Blood Pressure (DBP) — -5.71; -7.95; -9.35; -10.63 mmHg — p=<0.0001
Phase 3 N=271 Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years
Infections, Papillomavirus
Primary: Number of Subjects Who Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies — 112; 4; 106; 2…
Phase 3 N=354 Evaluation of the Immune and Safety Response of GlaxoSmithKline (GSK) Biologicals' HPV Vaccine in Healthy Indian Women
Infections, Papillomavirus
Primary: Number of Subjects Who Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies — 124; 16; 117; 4…
Phase 3 N=153 Atomoxetine to Treat Korean Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)
Attention Deficit Hyperactivity Disorder
Primary: Change From Baseline to Day 42 Endpoint in Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent Version: Investigator Administered and Scored…
Phase 3 N=584 Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed)
Bipolar Mania · Bipolar Disorder
Primary: Time to Intervention for a Mood Episode During Double Blind Period — 172.159; 143.133 Days — p=0.0104
Phase 3 N=413 A Study Comparing Montelukast With Placebo in Children With Seasonal Allergic Rhinitis (0476-219)(COMPLETED)
Seasonal Allergic Rhinitis
Primary: Number of Patients With Clinical Adverse Experiences (CAEs) — 73; 35; 207; 98 Participants
Phase 3 N=41 The Treatment of Acute Pulmonary Thromboembolism (PE) of GSK576428 (Fondaparinux Sodium) in Japanese Patients
Embolism, Pulmonary
Primary: The Percentage of Participants With Recurrent or New Symptomatic Venous Thromboembolism (VTE) — 0; 0 percentage of participants
Phase 3 N=750 SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
Carcinoma, Renal Cell
Primary: Progression-Free Survival (PFS), Core Radiology Assessment — 48.3; 22.1 weeks — p=<0.0001